Navigation Links
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
Date:10/29/2010

ALISO VIEJO, Calif., Oct. 29 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.  

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA).  PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying.  PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state.    

"The FDA approval of NUEDEXTA marks an important milestone for people living with PBA, an under-recognized and debilitating neurologic condition," said Keith Katkin, president and chief executive officer of Avanir.  "The approval of NUEDEXTA also marks AVANIR's transition toward becoming a commercial enterprise, ready to support the successful launch of the first FDA-approved treatment for PBA. We expect that NUEDEXTA will be available by prescription during the first quarter of 2011."

"This FDA approval represents a significant step forward for people who live with the debilitating effects of PBA," said Dr. Nicholas LaRocca, Vice President of Healthcare Delivery and Policy Research at the National MS Society. "For people who experience unexplained bouts of inappropriate laughing or crying, this new therapy has the potential to substantially help both them and their families."

"Today's approval of NUEDEXTA is a testament to the conviction of the patients and researchers who participated in our studies and represents over 10 years of research and development by our dedicated employees," said Randall Kaye, MD, Chief Medical Officer, AVANIR Pharmaceuticals. "We are very plea
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 IRIDEX Corporation (NASDAQ: ... second quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, August 6, 2015 ... other business developments. Interested parties may access ...
(Date:7/30/2015)...  Today we bring you a special edition of #MedicareMonday on Medicare,s 50 th ... of our Medicare resources and continue highlighting the success of the prescription drug benefit, ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... June 29 Omnicell, Inc ., (Nasdaq: ... facilities, today announced that its OmniCenter® server has achieved VMware Ready™ ... and testing process managed by VMware and is now listed on ... , , ...
... June 29 Mylan Inc. (Nasdaq: MYL ) today ... the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug ... Arimidex® Tablets, a treatment for early breast cancer. , ... Anastrozole Tablets had U.S. sales of approximately ...
Cached Medicine Technology:Omnicell's OmniCenter Achieves VMware Ready(TM) Healthcare Virtualization Status 2Omnicell's OmniCenter Achieves VMware Ready(TM) Healthcare Virtualization Status 3Mylan Receives Approval for Generic Version of Arimidex® Tablets 2
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam have ... the Apple AppStore. , The app is designed to track various metrics of ... tool to view personal health and use this information for positive behavior modification. Lume ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... , ... August 01, 2015 , ... Super Bowl 50 will emanate from ... League’s biggest day each year is the Super Bowl. In the two weeks that separate ... from the host venue. The 2016 Super Bowl game will mark the 50th time it ...
Breaking Medicine News(10 mins):Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Local Retail Advocate Wins National Recognition 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... prostate cancer earlier than ever before, but can,t accurately ... Health Research Institute,s Drs. John Lewis and Len Luyt, ... Ghrelin is a growth hormone produced by the ... cells are known to consume it at much higher ...
... Biomedical and Behavioral Research: Assessing the Necessity, a new ... request from the National Institutes of Health for expert ... research. The report will be released at a one-hour ... 15, in Room 100 of the National Academies, Keck ...
... is leading patients to seek out information about prescription ... in the International Journal Business and Systems Research. ... internet user through their physician there is a risk ... The direct advertising of pharmaceutical products to patients ...
... ANTONIO -- Obese patients with early-stage HER2-positive breast ... are normal weight or overweight, Mayo Clinic researchers found ... CTRC-AACR San Antonio Breast Cancer Symposium . HER2-positive breast ... epidermal growth factor receptor 2 that promotes cancer cell ...
... Mont., Dec. 7, 2011 LigoCyte Pharmaceuticals, Inc. ... protection against norovirus infection and related gastrointestinal illness ... sometimes referred to as "the stomach flu" is ... nausea, vomiting, abdominal cramps and diarrhea afflicting 21 ...
... 7 (HealthDay News) -- Obese women with early stage breast ... are of normal weight, new research suggests. Researchers from ... Wednesday at the 2011 San Antonio Breast Cancer Symposium. ... obesity, in general, increases a patient,s chance for having a ...
Cached Medicine News:Health News:Pharmaceutical spam 2Health News:Mayo Clinic: Obese patients with HER2-positive breast cancer may have worse outcomes 2Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 2Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 3Health News:NEJM publishes study showing LigoCyte's norovirus vaccine demonstrates protection against illness 4Health News:Obesity Linked to Worse Outcomes With Early Breast Cancer 2
Graether Collar Button micro iris retractor....
Round serrated handle, polished finish, overall length 130 mm....
... lens care solutions, when used ... ease of patient compliance in ... storage, wetting, rewetting and in-the-eye ... lenses (RGP or PMMA) of ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
Medicine Products: